Oscar R. Kronenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oscar R. Kronenberger has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa N. Kaser
Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas, TX 75235
3 shared publications - Colin Munro Cullum
Department of Psychiatry, University of Texas Southwestern Medical Center
3 shared publications - Jeff Schaffert
Department of Psychiatry, University of Texas Southwestern Medical Center
3 shared publications - Laura H. Lacritz
Department of Psychiatry, The University of Texas Southwestern Medical Center
3 shared publications - Christian LoBue
University of Texas Southwestern Medical Center
2 shared publications - Vishal J. Thakkar
University of Texas Southwestern Medical Center
2 shared publications
Latest Publications
- 8 July 2026
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- p. 1-10
Interplay of exercise engagement and emotional functioning on cognition in former college athletes
Engagement in healthy lifestyle behaviors plays a critical role in supporting healthy aging (Li et al., 2018), with health organizations worldwide advocating for increased physical activity and par...
- 8 July 2026
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- p. 1-10
Interplay of exercise engagement and emotional functioning on cognition in former college athletes
Engagement in healthy lifestyle behaviors plays a critical role in supporting healthy aging (Li et al., 2018), with health organizations worldwide advocating for increased physical activity and par...
- 30 May 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-12
Validity testing and beyond: Identifying and managing extraneous factors impacting interpretation of neuropsychological measures
Assessment of test validity is now a standard component of neuropsychological assessment. However, within a clinical, nonforensic setting, patients without clear incentive for intentional underperformance or exaggeration sometimes fall within established ranges for invalidity on validity test measures, resulting in interpretative challenges. This paper aims to provide an overview of the use of validity testing (VT) in the assessment of both intentional feigning of impairment and inadequate test engagement, factors that may impact both VT and neuropsychological test performance, and methods for promoting maximal engagement and effort during clinical evaluations. We discuss the evolution of VT in clinical neuropsychology documented in the literature as well as research addressing the impact of extraneous factors that may result in diminished test performances in a clinical context. We suggest strategies for managing some of these extraneous factors in terms of their impact on the overall evaluation, diagnostic formulation, and treatment planning. We include anecdotal examples in which validity testing may not be feasible or necessary, though with the understanding that our field has endorsed consensus statements on the use of VT in general. These consensus statements emphasize the necessity of routinely evaluating test validity, yet they also underscore the importance of interpreting findings within the broader clinical context. Within a clinical setting, neuropsychologists are equipped to interpret test data within the total context of the case and maximize patients' engagement to improve the degree of test validity in each evaluation.
- 30 May 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-12
Validity testing and beyond: Identifying and managing extraneous factors impacting interpretation of neuropsychological measures
Assessment of test validity is now a standard component of neuropsychological assessment. However, within a clinical, nonforensic setting, patients without clear incentive for intentional underperformance or exaggeration sometimes fall within established ranges for invalidity on validity test measures, resulting in interpretative challenges. This paper aims to provide an overview of the use of validity testing (VT) in the assessment of both intentional feigning of impairment and inadequate test engagement, factors that may impact both VT and neuropsychological test performance, and methods for promoting maximal engagement and effort during clinical evaluations. We discuss the evolution of VT in clinical neuropsychology documented in the literature as well as research addressing the impact of extraneous factors that may result in diminished test performances in a clinical context. We suggest strategies for managing some of these extraneous factors in terms of their impact on the overall evaluation, diagnostic formulation, and treatment planning. We include anecdotal examples in which validity testing may not be feasible or necessary, though with the understanding that our field has endorsed consensus statements on the use of VT in general. These consensus statements emphasize the necessity of routinely evaluating test validity, yet they also underscore the importance of interpreting findings within the broader clinical context. Within a clinical setting, neuropsychologists are equipped to interpret test data within the total context of the case and maximize patients' engagement to improve the degree of test validity in each evaluation.
- 23 December 2025
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 40 (3) , 753-775
Large language models in neuropsychology: Emerging applications and ethical considerations
Objective: There is immense excitement and fear regarding the potential of artificial intelligence, particularly large language models (LLMs), to transform healthcare services. In this paper, we aim to provide a future-oriented commentary on how neuropsychologists might consider integrating LLMs into clinical practice ethically, safely, and effectively. Methods: In Part 1, we provide a narrative review of the emerging applications of generative transformer-based LLMs in neuropsychological assessment, including how these technologies may support clinicians with data collection, clinical decision making, and documentation. In Part 2, we analyze the key ethical considerations using the framework of the American Psychological Association (APA) Ethical Principles of Psychologists and Code of Conduct (2017) and Ethical Guidance for AI in the Professional Practice of Health Service Psychology (2025) to formulate recommendations for future research, policy, and clinical integration. Conclusions: LLMs display promise for enhancing neuropsychological practice along a number of lines, such as extracting data from medical records and natural communication, automating test scoring, supporting differential diagnosis and treatment planning, developing test items, and generating text summaries of interviews and empirical literature. However, the rapid progress in LLMs over recent years has left little time for regulation, ethical discourse, and sufficient validation. Key barriers include privacy concerns, risk of bias, limited model transparency, threats to test security, and insufficient research supporting the validity and reliability across specialized tasks. We advise neuropsychologists to help shape regulation, lead empirical validation efforts, and augment educational resources to effectively integrate LLMs into clinical practice while maintaining high ethical standards.
- 23 December 2025
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 40 (3) , 753-775
Large language models in neuropsychology: Emerging applications and ethical considerations
Objective: There is immense excitement and fear regarding the potential of artificial intelligence, particularly large language models (LLMs), to transform healthcare services. In this paper, we aim to provide a future-oriented commentary on how neuropsychologists might consider integrating LLMs into clinical practice ethically, safely, and effectively. Methods: In Part 1, we provide a narrative review of the emerging applications of generative transformer-based LLMs in neuropsychological assessment, including how these technologies may support clinicians with data collection, clinical decision making, and documentation. In Part 2, we analyze the key ethical considerations using the framework of the American Psychological Association (APA) Ethical Principles of Psychologists and Code of Conduct (2017) and Ethical Guidance for AI in the Professional Practice of Health Service Psychology (2025) to formulate recommendations for future research, policy, and clinical integration. Conclusions: LLMs display promise for enhancing neuropsychological practice along a number of lines, such as extracting data from medical records and natural communication, automating test scoring, supporting differential diagnosis and treatment planning, developing test items, and generating text summaries of interviews and empirical literature. However, the rapid progress in LLMs over recent years has left little time for regulation, ethical discourse, and sufficient validation. Key barriers include privacy concerns, risk of bias, limited model transparency, threats to test security, and insufficient research supporting the validity and reliability across specialized tasks. We advise neuropsychologists to help shape regulation, lead empirical validation efforts, and augment educational resources to effectively integrate LLMs into clinical practice while maintaining high ethical standards.
- 8 December 2025
- Published by Oxford University Press (OUP) in Archives of Clinical Neuropsychology
- Vol. 41 (3)
Comparing the Neuropsychology Knowledge Base of Publicly Available Large Language Models
Objective: Assess the neuropsychology knowledge base of open-access large language models (LLMs) and inform potential applications in the field. Method: We obtained 600 multiple-choice practice questions from the “Be Ready for ABPP in Neuropsychology” website of the American Academy of Clinical Neuropsychology. We tested OpenAI (GPT-3.5, GPT-4, o3-mini-high) and Google (Gemini 1.0, 2.0 Flash Thinking Experimental [FTE]) models in two trials (T1: used 20-question blocks, T2: single-item re-administration of incorrect questions during T1). We compared AI-estimated to actual accuracy using a paired-samples t-test, while binomial logit generalized linear mixed-effects models (GLMMs) with a random intercept for item compared LLMs and item-level predictors (domain of practice, word count, position-in-block, and higher/lower order question type). Finally, we thematically analyzed the questions missed by the top models. Results: OpenAI o3-mini-high demonstrated the highest accuracy (T1:87.0%, T2:90.3%), followed by Gemini 2.0 FTE (T1:81.7%, T2:88.7%), GPT-4 (T1:74.0%, T2:85.5%), GPT-3.5 (T1:62.5%), and Gemini 1.0 (T1:52.3%). On average, LLMs overestimated their accuracy by 15.8% (87.3% vs. 71.5%, p < .001). In the GLMMs, specific LLM (p < .001) and practice domain (p = .045) were the only significant predictors of accuracy. Chain-of-thought “reasoning” models outperformed older models (p < .001) but displayed inaccuracies pertaining to aspects of neuropsychological testing and interpretation, diagnostic reasoning, clinical decision making, and neuroanatomy/neuroimaging. Conclusions: Chain-of-thought “reasoning” models displayed the highest accuracy, suggesting they may have utility in neuropsychology education, research, and clinical practice. However, the LLMs displayed persistent neuropsychology content area weaknesses and tended to present inaccurate information with confidence, highlighting the need for caution when interpreting LLM output.
- 8 December 2025
- Published by Oxford University Press (OUP) in Archives of Clinical Neuropsychology
- Vol. 41 (3)
Comparing the Neuropsychology Knowledge Base of Publicly Available Large Language Models
Objective: Assess the neuropsychology knowledge base of open-access large language models (LLMs) and inform potential applications in the field. Method: We obtained 600 multiple-choice practice questions from the “Be Ready for ABPP in Neuropsychology” website of the American Academy of Clinical Neuropsychology. We tested OpenAI (GPT-3.5, GPT-4, o3-mini-high) and Google (Gemini 1.0, 2.0 Flash Thinking Experimental [FTE]) models in two trials (T1: used 20-question blocks, T2: single-item re-administration of incorrect questions during T1). We compared AI-estimated to actual accuracy using a paired-samples t-test, while binomial logit generalized linear mixed-effects models (GLMMs) with a random intercept for item compared LLMs and item-level predictors (domain of practice, word count, position-in-block, and higher/lower order question type). Finally, we thematically analyzed the questions missed by the top models. Results: OpenAI o3-mini-high demonstrated the highest accuracy (T1:87.0%, T2:90.3%), followed by Gemini 2.0 FTE (T1:81.7%, T2:88.7%), GPT-4 (T1:74.0%, T2:85.5%), GPT-3.5 (T1:62.5%), and Gemini 1.0 (T1:52.3%). On average, LLMs overestimated their accuracy by 15.8% (87.3% vs. 71.5%, p < .001). In the GLMMs, specific LLM (p < .001) and practice domain (p = .045) were the only significant predictors of accuracy. Chain-of-thought “reasoning” models outperformed older models (p < .001) but displayed inaccuracies pertaining to aspects of neuropsychological testing and interpretation, diagnostic reasoning, clinical decision making, and neuroanatomy/neuroimaging. Conclusions: Chain-of-thought “reasoning” models displayed the highest accuracy, suggesting they may have utility in neuropsychology education, research, and clinical practice. However, the LLMs displayed persistent neuropsychology content area weaknesses and tended to present inaccurate information with confidence, highlighting the need for caution when interpreting LLM output.
- 23 August 2025
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- Vol. 33 (6) , 2003-2011
Prognostic utility of the Montreal Cognitive Assessment
The Montreal Cognitive Assessment (MoCA) is a widely applied cognitive screening instrument, with a supplemental Memory Index Score (MIS) which has been suggested to predict conversion from Mild Cognitive Impairment (MCI) to Alzheimer's Clinical Syndrome (ACS). This study compared the prognostic utility of the MIS to other MoCA metrics in predicting conversion to ACS or other dementias (OD). We analyzed National Alzheimer's Coordinating Center data from 2900 participants aged 50 years or older, diagnosed with MCI at baseline, with at least one follow-up visit. Multinomial logistic regression models assessed whether baseline MoCA Total Score (TS) or MIS predicted final diagnoses, and receiver operating characteristic (ROC) curves examined the clinical utility of baseline MoCA TS, MIS, Free Recall Score (FRS) and TS+MIS for identifying ACS converters at 1-, 3-, and 5-year follow-ups. Over an average follow-up of 4.65 years, 26.5% converted to ACS and 7.4% to OD. Higher baseline TS was associated with lower odds of conversion to ACS (OR = 0.82) and OD (OR = 0.86), while higher MIS was associated with lower odds of ACS (OR = 0.82) but not OD (OR = 0.97). For identifying ACS, ROC area under the curve ranges showed modest advantage for FRS (0.70-0.73), MIS (0.71-0.74), and TS+MIS (0.70-0.74) over the TS (0.63-0.70). MoCA memory subscores were the strongest baseline indicator of later ACS conversion, but no cut-off score displayed acceptable sensitivity and specificity. Future research may explore if MoCA memory subscores display greater prognostic utility in combination with other ACS features.
- 23 August 2025
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- Vol. 33 (6) , 2003-2011
Prognostic utility of the Montreal Cognitive Assessment
The Montreal Cognitive Assessment (MoCA) is a widely applied cognitive screening instrument, with a supplemental Memory Index Score (MIS) which has been suggested to predict conversion from Mild Cognitive Impairment (MCI) to Alzheimer's Clinical Syndrome (ACS). This study compared the prognostic utility of the MIS to other MoCA metrics in predicting conversion to ACS or other dementias (OD). We analyzed National Alzheimer's Coordinating Center data from 2900 participants aged 50 years or older, diagnosed with MCI at baseline, with at least one follow-up visit. Multinomial logistic regression models assessed whether baseline MoCA Total Score (TS) or MIS predicted final diagnoses, and receiver operating characteristic (ROC) curves examined the clinical utility of baseline MoCA TS, MIS, Free Recall Score (FRS) and TS+MIS for identifying ACS converters at 1-, 3-, and 5-year follow-ups. Over an average follow-up of 4.65 years, 26.5% converted to ACS and 7.4% to OD. Higher baseline TS was associated with lower odds of conversion to ACS (OR = 0.82) and OD (OR = 0.86), while higher MIS was associated with lower odds of ACS (OR = 0.82) but not OD (OR = 0.97). For identifying ACS, ROC area under the curve ranges showed modest advantage for FRS (0.70-0.73), MIS (0.71-0.74), and TS+MIS (0.70-0.74) over the TS (0.63-0.70). MoCA memory subscores were the strongest baseline indicator of later ACS conversion, but no cut-off score displayed acceptable sensitivity and specificity. Future research may explore if MoCA memory subscores display greater prognostic utility in combination with other ACS features.
- Open Access
- 18 August 2025
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 39 (3) , 261-276
A Scoping Review of Clinical Utility from the Montreal Cognitive Assessment Memory Index Score
Objective: The Montreal Cognitive Assessment (MoCA) Memory Index Score (MIS) is a supplemental assessment of memory composed of word list delayed free-recall followed by step-down category cued- and multiple-choice cued-recall. This paper reviews the MIS literature within Alzheimer’s and other neurodegenerative dementias to synthesize evidence regarding its clinical utility, identify gaps, and inform future research directions. Method: We searched electronic databases of OVID Medline, Embase, PsycINFO, and PubMed from 2014, when the MIS was first described, to July 2025. Peer-reviewed studies that reported data on the diagnostic or prognostic utility of the MIS in assessing neurodegenerative dementia populations were included. Results: We screened 278 articles, and 14 were included in the review. The current literature includes limited reporting on the diagnostic or prognostic utility of the MIS and is characterized by minimal diversity of samples and non-rigorous validation methods. Initial findings are promising and suggestive of incremental validity over the MoCA total score for identifying episodic memory impairment and therefore aiding in differentiation of suspected dementia etiology. However, evidence is insubstantial for the MIS as a tool for predicting progression and additional research is needed to evaluate the incremental validity of the MIS over the conventional MoCA five-word recall score. Conclusions: Large literature gaps exist regarding the clinical utility of the MIS within neurodegenerative dementias. Additional research exploring the psychometric properties of the MIS using diverse samples with rigorous validation methods is needed to better inform its application.
- 18 August 2025
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 39 (3) , 261-276
Open AccessA Scoping Review of Clinical Utility from the Montreal Cognitive Assessment Memory Index Score
Objective: The Montreal Cognitive Assessment (MoCA) Memory Index Score (MIS) is a supplemental assessment of memory composed of word list delayed free-recall followed by step-down category cued- and multiple-choice cued-recall. This paper reviews the MIS literature within Alzheimer’s and other neurodegenerative dementias to synthesize evidence regarding its clinical utility, identify gaps, and inform future research directions. Method: We searched electronic databases of OVID Medline, Embase, PsycINFO, and PubMed from 2014, when the MIS was first described, to July 2025. Peer-reviewed studies that reported data on the diagnostic or prognostic utility of the MIS in assessing neurodegenerative dementia populations were included. Results: We screened 278 articles, and 14 were included in the review. The current literature includes limited reporting on the diagnostic or prognostic utility of the MIS and is characterized by minimal diversity of samples and non-rigorous validation methods. Initial findings are promising and suggestive of incremental validity over the MoCA total score for identifying episodic memory impairment and therefore aiding in differentiation of suspected dementia etiology. However, evidence is insubstantial for the MIS as a tool for predicting progression and additional research is needed to evaluate the incremental validity of the MIS over the conventional MoCA five-word recall score. Conclusions: Large literature gaps exist regarding the clinical utility of the MIS within neurodegenerative dementias. Additional research exploring the psychometric properties of the MIS using diverse samples with rigorous validation methods is needed to better inform its application.